952059-56-2

Upstream product

• 15568-85-1 5-methoxymethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 65600-69-3 3-aminopyridine N-oxide hydrochloride 

Downstream Products

• 5423-54-1 4-hydroxy-1,5-naphthyridine 
• 952059-55-1 2-[2-methoxy-4-(1,7-naphthyridin-4-yloxy)phenyl]acetic acid 
• 952059-58-4 tert-butyl 2-[2-methoxy-4-(1,7-naphthyridin-4-yloxy)phenyl]acetate 
• 952059-67-5 2-[2-methoxy-4-(1,5-naphthyridin-4-yloxy)phenyl]acetic acid 
• 16287-97-1 4-chloro-[1,7]naphthyridine 
• 7689-63-6 4-chloro-1,5-naphthyridine 
• 60122-51-2 1,7-naphthyridin-4(1H)-one 

Relevant academic research and scientific papers

Strategic studies in the syntheses of novel 6,7-substituted quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones

This paper describes the different strategies devised and applied to overcome the selectivity issues in the syntheses of 6,7-disubstituted-1H-quinolin-4-one, 7-substituted-1H-1,6-naphthyridin-4-one and 6-substituted-1H-1,7-naphthyridin-4-one derivatives. They allowed us to improve the overall yields and the scaling-up feasibility. Several examples illustrate these strategies with their advantages and drawbacks.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

NAPHTHYRIDINE DERIVATIVES

The invention concerns naphthyridine derivatives of Formula (Ia) or (Ib) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, G1, G2, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders or disease states associated with angiogenesis and/or vascular permeability.